君实生物(01877.HK) 公布,特瑞普利单抗(产品代号:JS001)获得澳洲药品管理局(TGA)核准签发的上市许可,成为澳洲首个且唯一用于鼻咽癌的肿瘤免疫治疗药物。
适应症为特瑞普利单抗联合顺铂/吉西他滨作为转移性或复发性局部晚期鼻咽癌成人患者的一线治疗,以及作为单药治疗既往含铂治疗过程中或治疗后疾病进展的复发性、不可切除或转移性鼻咽癌的成人患者的上市许可申请已获得TGA批准。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2025-01-17 16:25。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.